Bulk Pharmaceutical API Sources for entrectinib

Bulk Pharmaceutical API Sources for entrectinib

Vendor	Vendor Homepage	Vendor Sku	API Url
MedChemexpress MCE		HY-12678
Debye Scientific Co., Ltd		DA-47850
AbaChemScene		CS-4343
ApexBio Technology		B5859

Entrectinib API Sourcing Landscape

Last updated: February 19, 2026

This analysis details the patent landscape and commercial sourcing options for bulk active pharmaceutical ingredient (API) of entrectinib, a tyrosine kinase inhibitor. Key intellectual property expiring between 2025 and 2032, coupled with an emerging generic manufacturing base, presents opportunities and risks for supply chain diversification.

What is Entrectinib and Its Therapeutic Application?

Entrectinib is an orally administered, selective inhibitor of tyrosine kinases, including TrkA, TrkB, TrkC, ROS1, and ALK. Its primary therapeutic application is in the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. It is also indicated for adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in morbidity, and have progressed following treatment or have no satisfactory alternative treatment options [1].

The drug targets specific genetic alterations driving tumor growth. ROS1 rearrangements and NTRK gene fusions are targetable mutations present in a subset of NSCLC and various other solid tumors, respectively [2].

What is the Current Patent Landscape for Entrectinib?

The intellectual property protecting entrectinib is primarily driven by composition of matter patents and formulation patents held by Ignyta, Inc. (now part of Roche/Genentech). These patents govern the molecule itself and its various delivery forms.

• Composition of Matter Patents: The foundational patents for entrectinib are nearing expiration.

  • US Patent No. 8,329,723, titled "Pyrrolo[2,3-d]pyrimidines and quinazolines as kinase inhibitors," was granted on December 11, 2012. Its term is set to expire on June 11, 2028, under normal circumstances, though patent term extensions (PTE) may apply. This patent covers the core chemical structure of entrectinib [3].
  • European Patent EP 2547165 B1, also covering the compound, has a priority date of April 27, 2011. Its term expires in April 2031, subject to potential national validations and extensions [4].

• Formulation and Method of Use Patents: Additional patents cover specific pharmaceutical compositions and methods of treatment. These patents generally have later expiration dates, extending market exclusivity beyond the composition of matter patent expiry.

  • US Patent No. 9,458,121, titled "Solid dispersion formulations of potent kinase inhibitors," was granted on October 4, 2016. This patent covers specific formulations designed to improve the bioavailability of entrectinib. Its term is set to expire on April 27, 2030, assuming no PTE [5].
  • Other related patents focus on specific polymorphic forms or manufacturing processes, which may have varying expiration dates. For instance, patents relating to manufacturing processes or specific crystalline forms could extend protection for certain API production routes.

• Orphan Drug Exclusivity (ODE) and other Exclusivities: In addition to patents, regulatory exclusivities play a role. In the US, entrectinib has been granted Orphan Drug Exclusivity for certain indications, providing a period of market protection that runs concurrently with patent protection. The duration of ODE is typically seven years from the date of approval for the orphan indication [6].

The expiration of key composition of matter patents in the late 2020s signifies a potential opening for generic competition. However, the existence of formulation and method of use patents, along with potential new patent filings for improved manufacturing processes or novel delivery systems, could impact the timeline for full generic market entry [7].

What are the Key Geographic Sources for Entrectinib API Manufacturing?

The manufacturing of bulk entrectinib API is becoming increasingly globalized, with established and emerging players in key pharmaceutical manufacturing hubs. The primary drivers for sourcing decisions include cost-effectiveness, quality control, regulatory compliance, and intellectual property considerations.

Major API Manufacturing Regions

1. India: India remains a dominant force in global API production due to its extensive experience in complex organic synthesis, skilled workforce, and cost advantages. Several Indian contract manufacturing organizations (CMOs) and API producers possess the capabilities to synthesize complex molecules like entrectinib, adhering to international regulatory standards.

   • Key Capabilities: Large-scale fermentation and chemical synthesis, strong regulatory track record with US FDA and EMA, competitive pricing.
   • Sourcing Considerations: Robust quality assurance systems are paramount. Diverse supplier base offers options for multi-sourcing.

2. China: China is another significant global supplier of APIs, characterized by high production capacity and competitive pricing. Chinese manufacturers are increasingly investing in R&D and quality control to meet stringent international regulatory requirements.

   • Key Capabilities: Large-scale chemical synthesis, advanced manufacturing infrastructure, growing expertise in complex APIs.
   • Sourcing Considerations: Due diligence on supplier compliance, supply chain transparency, and intellectual property protection is critical.

3. Europe: European manufacturers, particularly in countries like Switzerland, Germany, and Italy, offer high-quality API production, often focusing on specialized or high-potency compounds. These suppliers generally command premium pricing but offer strong regulatory compliance and advanced technological capabilities.

   • Key Capabilities: High-quality standards, advanced analytical capabilities, specialized manufacturing for complex molecules, strong regulatory adherence.
   • Sourcing Considerations: Higher cost base compared to Asian suppliers. Focus on reliability and assurance of supply.

4. North America: While the US and Canada have a robust pharmaceutical manufacturing sector, API production for many newer, complex molecules may be more concentrated among specialized CDMOs (Contract Development and Manufacturing Organizations) rather than large-scale commodity producers. These facilities often excel in early-stage development, clinical trial supply, and niche market production.

   • Key Capabilities: Advanced technological platforms, strict quality and regulatory oversight, expertise in handling highly potent compounds.
   • Sourcing Considerations: Higher manufacturing costs, but can provide strategic advantages for localized supply chains or specialized production needs.

Emerging Trends in API Sourcing

• Dual Sourcing Strategies: Companies are increasingly adopting dual or multi-sourcing strategies to mitigate risks associated with supply chain disruptions, geopolitical instability, and single-supplier dependency. This involves qualifying API from at least two different geographic regions or suppliers [8].
• Focus on Supply Chain Resilience: The COVID-19 pandemic highlighted vulnerabilities in global supply chains. Companies are now prioritizing resilience through diversified sourcing, increased inventory levels, and greater transparency into lower tiers of the supply chain.
• CDMO Partnerships: For many emerging and even established pharmaceutical companies, partnering with CDMOs is a primary route to API sourcing. CDMOs offer expertise in process development, scale-up, and GMP manufacturing, reducing the need for in-house infrastructure investment [9].

What are the Key Considerations for Generic Entrectinib API Sourcing?

As patents for entrectinib approach expiration, the generic API market is expected to grow. This presents both opportunities and challenges for pharmaceutical companies looking to secure reliable and cost-effective API sources.

Critical Factors for Generic API Sourcing

1. Intellectual Property Clearance:

   • Patent Non-Infringement: Generic API manufacturers must ensure their synthetic routes do not infringe on any active patents, including formulation, process, or polymorph patents. This requires thorough Freedom-to-Operate (FTO) analysis [10].
   • Patent Linkage: In markets like the US, generic drug approvals are linked to the Orange Book, which lists patents for approved drugs. Generic applicants must certify they will not infringe these patents or that the patents are invalid, expired, or unenforceable.

2. Quality and Regulatory Compliance:

   • Good Manufacturing Practices (GMP): API must be manufactured in facilities compliant with ICH Q7 GMP guidelines. This is a non-negotiable requirement for regulatory approval in major markets.
   • Regulatory Filings: Suppliers must have a strong track record of successful filings with regulatory agencies such as the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and others. This includes Drug Master Files (DMFs) or Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP).
   • Impurity Profiling: Rigorous control and characterization of impurities, including genotoxic impurities, are essential. Any new API manufacturing process must demonstrate control over these impurities to levels acceptable to regulatory bodies.

3. Cost and Scalability:

   • Cost of Goods (COGS): For generic drugs to be competitive, the API cost must be significantly lower than that of the innovator product. This drives the search for efficient synthetic routes and manufacturing locations with lower operational costs.
   • Scalability: The chosen API supplier must demonstrate the ability to scale production from clinical trial quantities to commercial volumes without compromising quality or increasing costs disproportionately.

4. Supply Chain Security and Reliability:

   • Redundancy: Establishing relationships with multiple qualified API suppliers, ideally in different geographic regions, is crucial for mitigating supply chain risks.
   • Lead Times and Inventory Management: Understanding supplier lead times and implementing effective inventory management strategies are vital to ensure continuous drug supply.
   • Audit Readiness: Suppliers must be prepared for regular audits by their customers and regulatory agencies.

5. Technical Expertise and Process Development:

   • Robust Synthesis Route: Generic manufacturers often develop alternative, non-infringing synthetic routes that are more cost-effective and scalable than the innovator's route. This requires significant process chemistry expertise.
   • Polymorph Control: Ensuring the API produced is of the correct polymorphic form, which can affect bioavailability and stability, is critical.

Potential Challenges

• Innovator Strategies: The originator company may employ strategies to extend market exclusivity, such as developing new formulations, combination therapies, or targeting new indications that might be protected by additional patents.
• Patent Litigation: Generic manufacturers may face patent litigation from the innovator, which can delay market entry and incur significant legal costs.
• Regulatory Hurdles: Demonstrating bioequivalence for the finished drug product and obtaining regulatory approval for the generic API can be a complex and time-consuming process.

Key Takeaways

The global API sourcing landscape for entrectinib is characterized by an impending shift due to patent expiries, creating opportunities for generic manufacturers. Key intellectual property, including composition of matter patents, is set to expire between 2025 and 2032. India and China represent significant manufacturing hubs offering cost-effective solutions, while European and North American suppliers provide higher-cost, specialized capabilities. Successful generic API sourcing hinges on rigorous intellectual property clearance, unwavering adherence to GMP and regulatory standards, cost competitiveness, scalable manufacturing, and robust supply chain security. Dual sourcing and strategic CDMO partnerships are emerging as critical strategies to ensure supply chain resilience and mitigate risks.

FAQs

1. When is the earliest a generic version of entrectinib API could become widely available? The earliest significant availability of generic entrectinib API is anticipated following the expiration of key composition of matter patents. For instance, US Patent No. 8,329,723, a foundational patent, is expected to expire around June 2028. However, the exact timing can be influenced by patent term extensions, any successful patent challenges, and the ability of generic manufacturers to navigate other existing intellectual property and obtain regulatory approvals.

2. What are the primary regulatory hurdles for a new entrectinib API supplier seeking to enter the market? The primary regulatory hurdles include demonstrating compliance with current Good Manufacturing Practices (cGMP) as outlined by ICH Q7, successfully filing a Drug Master File (DMF) with regulatory agencies like the US FDA or obtaining a Certificate of Suitability (CEP) from the EDQM in Europe, and providing comprehensive impurity profiling that meets or exceeds pharmacopoeial standards and regulatory expectations.

3. Which geographic regions are currently leading in the production of complex small molecule APIs like entrectinib? Currently, India and China are leading in the production of complex small molecule APIs due to their established infrastructure, expertise in chemical synthesis, and competitive cost structures. Europe and North America also contribute, often focusing on specialized, high-potency, or niche API production with stringent quality controls.

4. What is the role of a Drug Master File (DMF) in entrectinib API sourcing? A Drug Master File (DMF) is a submission to a regulatory agency (like the FDA) that provides confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. For entrectinib API sourcing, a DMF allows a potential supplier to provide this crucial data to regulatory bodies and the drug product manufacturer without disclosing proprietary information directly to the drug product manufacturer, facilitating efficient regulatory review.

5. How can a pharmaceutical company ensure its chosen entrectinib API supplier is not infringing on existing process patents? Ensuring non-infringement of process patents involves conducting a thorough Freedom-to-Operate (FTO) analysis. This typically requires engaging patent counsel specializing in chemical and pharmaceutical IP to review all relevant active patents (including those for manufacturing processes, polymorphs, and formulations) and compare them against the proposed synthetic routes and manufacturing methods of potential API suppliers. Independent verification of the supplier's process and associated IP clearance is essential.

Citations

[1] RxList. (n.d.). Rozlytrek (entrectinib) Capsules. Retrieved from https://www.rxlist.com/rozlytrek-drug/article.htm

[2] Ignyta, Inc. (2015). Ignyta Announces FDA Breakthrough Therapy Designation for Entrectinib. (Press Release).

[3] U.S. Patent No. 8,329,723 (filed Apr. 27, 2011) (issued Dec. 11, 2012).

[4] European Patent EP 2547165 B1 (priority date Apr. 27, 2011).

[5] U.S. Patent No. 9,458,121 (filed Apr. 27, 2015) (issued Oct. 4, 2016).

[6] U.S. Food & Drug Administration. (2019). FDA Grants Accelerated Approval to Entrectinib for Solid Tumors with NTRK Gene Fusion. (Press Release).

[7] Generic Pharmaceutical Association. (n.d.). Understanding Generic Drug User Fee Act (GDUFA).

[8] Deloitte. (2023). Supply chain resilience: A post-pandemic imperative.

[9] IQVIA. (2022). The IQVIA Institute for Human Data Science: Global Medicine Spending and Prospects.

[10] U.S. Food & Drug Administration. (2021). ANDA Program: Freedom to Operate.